Patent Cooperation Treaty

Aerwins Patented Air Mobility Platform to Revolutionize Low Altitude Flights for Vehicles Opening Flight Possibilities for Electric Vehicles

Retrieved on: 
Monday, July 17, 2023
JCAB, Patent, Alef Aeronautics, Altitude, Travel, EV, Investment, Atmosphere, Marketing, Internet, Perception, Model A, Urban Air Mobility, Edison Award, Research, Patent Cooperation Treaty, McKinsey & Company, Joint venture, Movement, Japan Civil Aviation Bureau, FAA, Zawar Farid, Certification, EVS, Security, The Company, Third place, Engineering, City, Tourism, MAK Technologies, Inc., United Arab Emirates, Edison Awards, Safety, Transport, Electric motor, Film industry, Recreation

The Company's one-of-a-kind patent-protected design blends the practicality of electric cars with the thrill of airborne travel, providing a clear, integrated solution for current electric vehicles (EV).

Key Points: 
  • The Company's one-of-a-kind patent-protected design blends the practicality of electric cars with the thrill of airborne travel, providing a clear, integrated solution for current electric vehicles (EV).
  • AERWINS' advanced technology revolutionizes low-altitude air mobility for vehicles.
  • Its superior design allows it to integrate with many EVs and transform a typical electric car into a flying vehicle.
  • AERWINS aims to be a high-performance company in the Low Altitude and Ultra Low Altitude categories."

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

Retrieved on: 
Wednesday, July 5, 2023
Biologics license application, Patent, Intellectual property, Letter, EPI, Food, CFA, Exocrine pancreatic insufficiency, United States Patent and Trademark Office, Clinical trial, BOCA, Quality of life, First wave, Cystic fibrosis, Patent Cooperation Treaty, IP, CNA, PCT, Stomach, PERT, Public expenditure, World Organization of the Scout Movement, Capsule, Patient, Cystic Fibrosis Foundation, WIPO, Growth, SPAN, Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CF, BLA, Safety, Gastrointestinal disease, Malabsorption, Pharmaceutical industry, Holding company, Shareholder

BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.

Key Points: 
  • BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.
  • We are pleased to announce that the last patient in the study has completed their last visit.
  • On June 22, 2023, First Wave held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) during which stockholders had the opportunity to vote on five proposals.
  • As always, I extend my appreciation to our stockholders for your continued support.

First Wave BioPharma Strengthens Intellectual Property Estate

Retrieved on: 
Tuesday, June 27, 2023
Patent, EPI, CFA, Exocrine pancreatic insufficiency, United States Patent and Trademark Office, BOCA, First wave, Patent Cooperation Treaty, IP, PCT, CNA, World Organization of the Scout Movement, Publication, Patient, Cystic fibrosis, WIPO, SPAN, CFA Institute, Safety, Malabsorption, Pharmaceutical industry

The PCT includes 157 countries and covers virtually all worldwide industrialized markets.

Key Points: 
  • The PCT includes 157 countries and covers virtually all worldwide industrialized markets.
  • “The patent publications for our enhanced enteric microgranule delivery formulation of adrulipase and its use for the treatment of malabsorption highlight First Wave’s ability to introduce important drug innovations for the treatment of underserved disease indications,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • The Phase 2b SPAN trial is designed to investigate the safety, tolerability, and efficacy of a new enteric microgranulation formulation of adrulipase.
  • Patients will be screened at baseline to ensure that they have a coefficient of fat absorption (CFA) of at least 80%.

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, June 8, 2023
AFD, Temporomandibular joint dysfunction, SEC filing, Migraine, TMD, DME, Marketing, Patent Cooperation Treaty, DSO, OSA, Sale, Organization, Net, Dentist, Vivos, Traction, Dental Service Organizations, Patent, Patient, Acquisition, Webcast, Security (finance), FDA, Durable medical equipment, Therapy, Very important person, VIP, Pharmaceutical industry, Cryptocurrency, Bruxism

LITTLETON, Colo., June 08, 2023 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, today reported financial results and operating highlights for the first quarter ended March 31, 2023.

Key Points: 
  • As of March 31 2023, patients treated with The Vivos Method totaled over 35,000, compared to approximately 28,000 as of the first quarter of 2022.
  • The study demonstrated statistically significant results, with ninety-two percent (92%) of study patients reporting their migraine symptoms were completely resolved following completion of treatment.
  • “Vivos is evolving into a more scalable and sustainable growth company with a clear path to cash flow positive operations.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .

OPPO Releases 2022 Sustainability Report on World Environment Day

Retrieved on: 
Monday, June 5, 2023
IDC, Heart, Kindness, Life, OPPO, Carbon footprint, Smartphone, Health, ECG, Research, Patent Cooperation Treaty, Carbon, PCT, Thermoregulation, H1, ColorOS, Sustainability, Sustainability reporting, World Intellectual Property Organization, Challenge, American Hearing Impaired Hockey Association, WIPO, Ecosystem, Heart rate, Family, Renewable energy, Mobile phone, Typesetting, Green Dot

Shenzhen, China--(Newsfile Corp. - June 5, 2023) - OPPO releases its 2022 Sustainability Report on World Environment Day this year.

Key Points: 
  • Shenzhen, China--(Newsfile Corp. - June 5, 2023) - OPPO releases its 2022 Sustainability Report on World Environment Day this year.
  • Starting in 2020, OPPO has published the Sustainability Report each year to publicly disclose its plans and practical progress towards sustainability goals.
  • The report highlights the significant progress that OPPO has made in five key areas of sustainability, including: operation and compliance, environment protection, caring for employees, virtuous innovation and ecosystem engagement, reinforcing OPPO's commitment to sustainability.
  • In 2022, OPPO ranked among the top 6 Patent Cooperation Treaty (PCT) filers according to the World Intellectual Property Organization (WIPO).

OPPO Release 2022 Sustainability Report on World Environment Day

Retrieved on: 
Monday, June 5, 2023
IDC, Heart, Kindness, Life, OPPO, Smartphone, Huber loss, Health, ECG, Research, Patent Cooperation Treaty, Carbon, PCT, Thermoregulation, H1, ColorOS, World Environment Day, Sustainability, Sustainability reporting, World Intellectual Property Organization, Challenge, WIPO, Ecosystem, Heart rate, Family, Renewable energy, Mobile phone, EU, Green Dot

SHENZHEN, CHINA - Media OutReach – 5 June 2023 – OPPO releases its 2022 Sustainability Report on World Environment Day this year.

Key Points: 
  • SHENZHEN, CHINA - Media OutReach – 5 June 2023 – OPPO releases its 2022 Sustainability Report on World Environment Day this year.
  • Starting in 2020, OPPO has published the Sustainability Report each year to publicly disclose its plans and practical progress towards sustainability goals.
  • At OPPO, sustainability is not just a simple word for the World Environment Day, but a practice and a commitment in the long run.
  • To learn about OPPO’s journey on sustainability, please check OPPO Sustainability Report 2022 .

Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

Retrieved on: 
Wednesday, May 24, 2023
Retina, Patent Cooperation Treaty, PCT, Application, OTC, Metformin, RPE, Rare, Choroid

Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25, 2022. 

Key Points: 
  • Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina
    Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S.
  • Receiving Office on May 22, 2023, claiming priority to U.S.
  • 63/345,759, filed May 25, 2022.
  • The Application has been accorded International Application No.

NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 24, 2023
Patent, Rat, Intellectual property, Reflex, TSX Venture Exchange, Central nervous system, Tetraplegia, United States Patent and Trademark Office, Spinal cord, Option, Exosome, FSE, Research, Patent Cooperation Treaty, PCT, CNS, NRX, Small RNA, Administration, TEL, Patient, PTEN, Growth, The Company, Pharmaceutical industry, Cryptocurrency

As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.

Key Points: 
  • As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.
  • Research and development expenses were US$0.37 million in the first quarter of 2023, compared to US$0.28 million in the same quarter in 2022.
  • Financial (income) expenses were (US$0.01) million in the first quarter of 2023, compared to US$0.09 million in the same period in 2022.
  • Net loss was US$0.70 million in the first quarter of 2023, compared to a net loss of US$2.31 million in the first quarter of 2022.

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, Mental Health, Alternative Medicine, Health, Pharmaceutical, Psilocybin, Patent, Depression, Therapy, Anxiety, United States Patent and Trademark Office, ISR, Patent Cooperation Treaty, IP, PCT, Prodrug, Addiction, Anxiety disorder, NCE, Family, Mental health, Pharmaceutical industry, Enver Pasha

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.
  • The soon-to-issue patent, titled, “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.
  • The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.
  • Additionally, Enveric has filed further composition of matter patent applications with the USPTO for psilocin prodrugs, including compositions comprising a crystalline molecular structure.

Versus Systems Secures New U.S. Patent for Machine Learning and Artificial Intelligence System

Retrieved on: 
Wednesday, May 10, 2023
Patent, VS, ML, Patent Cooperation Treaty, Machine learning, Artificial intelligence, AI, Video game

- a patent that describes uses of machine learning and artificial intelligence (AI) that can optimize in-game coupons and rewards for both the player and the prize-providing brand.

Key Points: 
  • - a patent that describes uses of machine learning and artificial intelligence (AI) that can optimize in-game coupons and rewards for both the player and the prize-providing brand.
  • Versus’ new patent, which has a priority date of March 11, 2020, was issued by the USPTO on May 9, 2023.
  • This is the sixth patent that the USPTO has issued to Versus on the subject of interactive media and in-game rewards and it is Versus seventh patent overall.
  • Machine Learning is going to help make Versus-enabled interactive media more engaging, more fun, with better value for all involved.”